{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:32:36Z","timestamp":1787646756991,"version":"build-2736575974"},"reference-count":50,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2021,1,19]]},"abstract":"<jats:p>Background: Brevican and neurocan are central nervous system-specific extracellular matrix proteoglycans. They are degraded by extracellular enzymes, such as metalloproteinases. However, their degradation profile is largely unexplored in cerebrospinal fluid (CSF). Objective: The study aim was to quantify proteolytic peptides derived from brevican and neurocan in human CSF of patients with Alzheimer\u2019s disease (AD) and vascular dementia (VaD) compared with controls. Methods: The first cohort consisted of 75 individuals including 25 patients with AD, 7 with mild cognitive impairment (MCI) diagnosed with AD upon follow-up, 10 patients with VaD or MCI diagnosed with VaD upon follow-up, and 33 healthy controls and cognitively stable MCI patients. In the second cohort, 31 individuals were included (5 AD patients, 14 VaD patients and 12 healthy controls). Twenty proteolytic peptides derived from brevican (n = 9) and neurocan (n = 11) were quantified using high-resolution parallel reaction monitoring mass spectrometry. Results: In the first cohort, the majority of CSF concentrations of brevican and neurocan peptides were significantly decreased inVaDas compared withADpatients (AUC\u00a0=\u00a00.83.0.93, p\u22640.05) and as compared with the control group (AUC\u00a0=\u00a00.79.0.87, p\u00a0\u2264\u00a00.05). In the second cohort, CSF concentrations of two brevican peptides (B87, B156) were significantly decreased in VaD compared with AD (AUC\u00a0=\u00a00.86.0.91, p\u00a0\u2264\u00a00.05) and to controls (AUC\u00a0=\u00a00.80.0.82, p\u00a0\u2264\u00a00.05), while other brevican and neurocan peptides showed a clear trend to be decreased in VaD compared with AD (AUC\u00a0=\u00a00.64.80, p\u00a0&gt;\u00a00.05). No peptides differed between AD and controls. Conclusion: Brevican and neurocan peptides are potential diagnostic biomarkers for VaD, with ability to separate VaD from AD.<\/jats:p>","DOI":"10.3233\/jad-201039","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T10:24:34Z","timestamp":1608287074000},"page":"729-741","source":"Crossref","is-referenced-by-count":23,"title":["Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"79","author":[{"given":"Karolina","family":"Minta","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Neurochemistry,Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Brinkmalm","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry,Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Portelius","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry,Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Helsingborg, Lund University, Sweden"},{"name":"Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Svensson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Endocrinology, Skaraborg Central Hospital, Sk\u00f6vde, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella","family":"Kettunen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry,Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wallin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry,Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry,Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"},{"name":"Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK"},{"name":"UK Dementia Research Institute at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry,Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Andreasson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry,Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-201039_ref1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer\u2019s disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.3233\/JAD-201039_ref2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"10.3233\/JAD-201039_ref3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/JAD-201039_ref4","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(06)68542-5","article-title":"Mild cognitive impairment","volume":"367","author":"Gauthier","year":"2006","journal-title":"Lancet"},{"key":"10.3233\/JAD-201039_ref5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jamda.2016.06.020","article-title":"Spontaneous reversion of mild cognitive impairment to normal cognition: A systematic review of literature and meta-analysis","volume":"17","author":"Canevelli","year":"2016","journal-title":"J Am Med Dir Assoc"},{"key":"10.3233\/JAD-201039_ref6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1212\/WNL.51.3.728","article-title":"The incidence of dementia: A meta-analysis","volume":"51","author":"Jorm","year":"1998","journal-title":"Neurology"},{"key":"10.3233\/JAD-201039_ref7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.expneurol.2015.05.006","article-title":"Models and mechanisms of vascular dementia","volume":"272","author":"Venkat","year":"2015","journal-title":"Exp Neurol"},{"key":"10.3233\/JAD-201039_ref8","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/S0140-6736(15)00463-8","article-title":"Vascular dementia","volume":"386","author":"O\u2019Brien","year":"2015","journal-title":"Lancet"},{"key":"10.3233\/JAD-201039_ref9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/089198879300600307","article-title":"Heterogeneity of vascular dementia: Mechanisms and subgroups","volume":"6","author":"Wallin","year":"1993","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.3233\/JAD-201039_ref10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12916-014-0206-2","article-title":"The overlap between vascular disease and Alzheimer\u2019s disease\u2013lessons from pathology","volume":"12","author":"Attems","year":"2014","journal-title":"BMC Med"},{"key":"10.3233\/JAD-201039_ref11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-201039_ref12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-201039_ref13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"issue":"Suppl 3","key":"10.3233\/JAD-201039_ref14","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1097\/00002093-199912003-00017","article-title":"Overlap between pathology of Alzheimer disease and vascular dementia","volume":"13","author":"Kalaria","year":"1999","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-201039_ref15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1468-1331.2008.02387.x","article-title":"CSF biomarker profile and diagnostic value in vascular dementia","volume":"16","author":"Paraskevas","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-201039_ref16","doi-asserted-by":"crossref","first-page":"5214961","DOI":"10.1155\/2016\/5214961","article-title":"Neuron-glia interactions in neural plasticity: Contributions of neural extracellular matrix and perineuronal nets","volume":"2016","author":"Dzyubenko","year":"2016","journal-title":"Neural Plast"},{"key":"10.3233\/JAD-201039_ref17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cne.20822","article-title":"Composition of perineuronal nets in the adult rat cerebellum and the cellular origin of their components","volume":"494","author":"Carulli","year":"2006","journal-title":"J Comp Neurol"},{"key":"10.3233\/JAD-201039_ref18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1242\/dmm.004077","article-title":"Remodeling and homeostasis of the extracellular matrix: Implications for fibrotic diseases and cancer","volume":"4","author":"Cox","year":"2011","journal-title":"Dis Model Mech"},{"key":"10.3233\/JAD-201039_ref19","doi-asserted-by":"crossref","first-page":"10119","DOI":"10.1016\/S0021-9258(17)36998-3","article-title":"Molecular cloning of brevican, a novel brain proteoglycan of the aggrecan\/versican family","volume":"269","author":"Yamada","year":"1994","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-201039_ref20","doi-asserted-by":"crossref","first-page":"22695","DOI":"10.1074\/jbc.M909764199","article-title":"Brain-enriched hyaluronan binding (BEHAB)\/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member","volume":"275","author":"Matthews","year":"2000","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-201039_ref21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2202-6-52","article-title":"Evidence for proteolytic cleavage of brevican by the ADAMTSs in the dentate gyrus after excitotoxic lesion of the mouse entorhinal cortex","volume":"6","author":"Mayer","year":"2005","journal-title":"BMC Neurosci"},{"key":"10.3233\/JAD-201039_ref22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.matbio.2015.01.014","article-title":"ADAMTS expression and function in central nervous system injury and disorders","volume":"44-46","author":"Gottschall","year":"2015","journal-title":"Matrix Biol"},{"key":"10.3233\/JAD-201039_ref23","doi-asserted-by":"crossref","first-page":"38885","DOI":"10.1074\/jbc.M003875200","article-title":"Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites","volume":"275","author":"Nakamura","year":"2000","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-201039_ref24","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1523\/JNEUROSCI.20-07-02427.2000","article-title":"Neurocan is upregulated in injured brain and in cytokine-treated astrocytes","volume":"20","author":"Asher","year":"2000","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-201039_ref25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0197-0186(94)90018-3","article-title":"Immunological identification of two proteoglycan fragments derived from neurocan, a brain-specific chondroitin sulfate proteoglycan","volume":"25","author":"Matsui","year":"1994","journal-title":"Neurochem Int"},{"key":"10.3233\/JAD-201039_ref26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.33594\/000000069","article-title":"Neurocan is a new substrate for the ADAMTS12 metalloprotease: Potential implications in neuropathies","volume":"52","author":"Fontanil","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"10.3233\/JAD-201039_ref27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/90273","article-title":"Determination of protease cleavage site motifs using mixture-based oriented peptide libraries","volume":"19","author":"Turk","year":"2001","journal-title":"Nat Biotechnol"},{"key":"10.3233\/JAD-201039_ref28","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1016\/j.bbagen.2017.06.010","article-title":"Formation and remodeling of the brain extracellular matrix in neural plasticity: Roles of chondroitin sulfate and hyaluronan","volume":"1861","author":"Miyata","year":"2017","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.3233\/JAD-201039_ref29","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3233\/JAD-190187","article-title":"Cerebrospinal fluid concentrations of extracellular matrix proteins in Alzheimer\u2019s disease","volume":"69","author":"Minta","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-201039_ref30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3233\/JAD-2011-101878","article-title":"Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: Diagnostic performance in a homogeneous mono-center population","volume":"24","author":"Johansson","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-201039_ref31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/10401239409149001","article-title":"Diagnostic and statistical manual of mental disorders, 3rd ed. (DSM-III), adaptive functioning in young Swedish suicides","volume":"6","author":"Runeson","year":"1994","journal-title":"Ann Clin Psychiatry"},{"key":"10.3233\/JAD-201039_ref32","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.3233\/JAD-201039_ref33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med"},{"key":"10.3233\/JAD-201039_ref34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","article-title":"Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop","volume":"43","author":"Roman","year":"1993","journal-title":"Neurology"},{"key":"10.3233\/JAD-201039_ref35","first-page":"23","article-title":"Research criteria for subcortical vascular dementia in clinical trials","volume":"59","author":"Erkinjuntti","year":"2000","journal-title":"J Neural Transm Suppl"},{"key":"10.3233\/JAD-201039_ref36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/jcbfm.2015.147","article-title":"The Gothenburg MCI study: Design and distribution of Alzheimer\u2019s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up","volume":"36","author":"Wallin","year":"2016","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JAD-201039_ref37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/jms.2987","article-title":"An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid","volume":"47","author":"Brinkmalm","year":"2012","journal-title":"J Mass Spectrom"},{"key":"10.3233\/JAD-201039_ref38","doi-asserted-by":"publisher","DOI":"10.1002\/prca.201700131"},{"key":"10.3233\/JAD-201039_ref39","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1373\/clinchem.2005.049429","article-title":"Development of a high-throughput automated analyzer using biochip array technology","volume":"51","author":"Fitzgerald","year":"2005","journal-title":"Clin Chem"},{"key":"10.3233\/JAD-201039_ref40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2011.00001","article-title":"Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases","volume":"3","author":"Rosen","year":"2011","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-201039_ref41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","article-title":"Cerebrospinal fluid microglial markers in Alzheimer\u2019s disease: Elevated chitotriosidase activity but lack of diagnostic utility","volume":"13","author":"Mattsson","year":"2011","journal-title":"Neuromolecular Med"},{"key":"10.3233\/JAD-201039_ref42","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.psyneuen.2013.02.006","article-title":"Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer\u2019s disease","volume":"38","author":"Johansson","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.3233\/JAD-201039_ref43","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.3390\/ijms20112812","article-title":"Emerging biomarkers in vascular cognitive impairment and dementia: From pathophysiological pathways to clinical application","volume":"20","author":"Cipollini","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-201039_ref44","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","article-title":"Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction","volume":"25","author":"Nation","year":"2019","journal-title":"Nat Med"},{"key":"10.3233\/JAD-201039_ref45","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/alz.12061","article-title":"A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid","volume":"16","author":"Sweeney","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-201039_ref46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCRESAHA.116.308426","article-title":"Vascular cognitive impairment","volume":"120","author":"Dichgans","year":"2017","journal-title":"Circ Res"},{"key":"10.3233\/JAD-201039_ref47","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.STR.32.5.1162","article-title":"White matter damage is associated with matrix metalloproteinases in vascular dementia","volume":"32","author":"Rosenberg","year":"2001","journal-title":"Stroke"},{"key":"10.3233\/JAD-201039_ref48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3233\/JAD-2011-110566","article-title":"Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer\u2019s disease","volume":"27","author":"Bjerke","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-201039_ref49","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1161\/01.STR.0000127420.10990.76","article-title":"Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease","volume":"35","author":"Adair","year":"2004","journal-title":"Stroke"},{"key":"10.3233\/JAD-201039_ref50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neurobiolaging.2007.07.015","article-title":"Blood-brain barrier: Ageing and microvascular disease\u2013systematic review and meta-analysis","volume":"30","author":"Farrall","year":"2009","journal-title":"Neurobiol Aging"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-201039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:39Z","timestamp":1777370679000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-201039"}},"subtitle":[],"editor":[{"given":"Jagan","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":50,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-201039","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]}}}